Mersana Therapeutics (MRSN) said Friday that the US Food and Drug Administration recently granted an additional Fast Track designation to XMT-1660 for the treatment of advanced or metastatic breast cancer in patients with human epidermal growth factor receptor 2 low or HER2-negative disease, including triple-negative breast cancer, who have received a prior topoisomerase-1 inhibitor antibody-drug conjugate, the company said.
The FDA previously granted the drug Fast Track designation for the treatment of adult patients with advanced or metastatic recurrent triple-negative breast cancer.
The company also said that the World Health Organization has approved emiltatug ledadotin as XMT-1660's international nonproprietary name.
Shares of the company were up more than 15% in Friday's premarket activity.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。